Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDX227675 in Hyperkalemia
NCT03018067Phase 2Terminated
- Sponsor
- Ardelyx
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rdx022 in hyperkalemia, sponsored by Ardelyx. Started Jan 2017; status: terminated.
02
Drugs
rdx022
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT03018067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018067.